While Vedanta Biosciences waits for a phase 3 readout for its lead microbiome therapy based on live bacteria, an earlier-stage programme has failed a mid-stage trial. The Cambridge, ...
The high value attached by pharma companies to inflammation and immunology (I&I) programmes is on display once again, as AbbVie agrees a deal worth up to $1.7 billion for an inflammatory bowel disease ...
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results